Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Devimistat by Cornerstone Pharmaceuticals for Unspecified B-Cell Lymphomas: Likelihood of Approval
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Unspecified B-Cell Lymphomas. According to GlobalData,...
Data Insights
Devimistat by Cornerstone Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...